Tasquinimod

Last updated
Tasquinimod
Chemical structure of tasquinimod.svg
Legal status
Legal status
  • Experimental
Pharmacokinetic data
Elimination half-life 40 ± 16 hours [1]
Identifiers
  • 4-Hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[4-(trifluoromethyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C20H17F3N2O4
Molar mass 406.361 g·mol−1
3D model (JSmol)
  • CN1C2=C(C(=CC=C2)OC)C(=C(C1=O)C(=O)N(C)C3=CC=C(C=C3)C(F)(F)F)O
  • InChI=1S/C20H17F3N2O4/c1-24(12-9-7-11(8-10-12)20(21,22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10,26H,1-3H3 Yes check.svgY
  • Key:ONDYALNGTUAJDX-UHFFFAOYSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)

Tasquinimod (ABR-215050, CID 54682876) is an experimental drug currently being investigated for the treatment of solid tumors. Tasquinimod has been mostly studied in prostate cancer, but its mechanism of action suggests that it could be used to treat other cancers. Castration-resistant prostate cancer (CRPC), formerly called hormone-resistant or hormone-refractory prostate cancer, is prostate cancer that grows despite medical or surgical androgen deprivation therapy. Tasquinimod targets the tumor microenvironment and counteracts cancer development by inhibiting angiogenesis and metastasis and by modulating the immune system. [2] [3] [4] [5] It is now in phase III development, [6] [7] following successful phase II trial outcomes. [7] [8] [9]

Contents

History

Collaborative studies by laboratories at Johns Hopkins School of Medicine and Active Biotech Research AB identified tasquinimod as the lead agent for developing a treatment for prostate cancer. [2] [10] [11] Tasquinimod was one of several second-generation quinoline-3-carboxamide variants synthesized using the drug roquinimex as a starting point, and it performed well in pre-clinical studies of cancer models. [2] [11] [12] [13]

In April 2011, Ipsen and Active Biotech entered into a broad partnership for the co-development of tasquinimod for the treatment of cancer. Active Biotech granted Ipsen exclusive rights to commercialize tasquinimod worldwide, except in North and South America and Japan where Active Biotech retained all commercial and marketing rights. [14]

Mechanism of action

Tasquinimod is a novel small-molecule inhibitor that targets the tumor microenvironment by controlling the accumulation and immunosuppressive, pro-angiogenic and pro-metastatic functions of regulatory myeloid cells (also called myeloid-derived suppressor cells). [2] [4] [5] [15] It binds to and inhibits the interactions of S100A9, an immunomodulatory protein that promotes tumor development, [16] influences suppressive and pro-angiogenic cells in the tumor microenvironment, [16] [17] [18] and participates in the establishment of pre-metastatic niches. [17]

Tasquinimod may also target the tumor microenvironment by suppressing the tumor hypoxic response, in which genes involved in the adaptation and survival of cells during hypoxia are induced. [3] Tasquinimod reduces tumor angiogenesis; but its anti-angiogenic effects do not appear to be linked to vascular endothelial growth factor (VEGF) neutralization or VEGF receptor tyrosine kinase inhibition. [2] [13]

Clinical studies

A randomized, double-blind, placebo-controlled phase II study comparing tasquinimod with placebo in 206 men with metastatic CRPC was completed in 2009. [8] The primary endpoint in the trial was to show a difference in the number of patients with disease progression at 6 months. [8] The proportion of patients who were disease progression-free after 6 months was 69% for patients treated with tasquinimod versus 37% for placebo-treated patients (p<0.001). [8] Median progression-free survival (PFS) was significantly improved in patients treated with tasquinimod compared with patients receiving placebo (7.6 vs 3.3 months; hazard ratio [HR] 0.57; 95% confidence interval [CI] 0.39, 0.85, p=0.0042). [8] Tasquinimod thus delayed disease progression by about 4.3 months. Overall survival (OS) observed for tasquinimod-treated patients was longer than previously reported in this patient population. [9] Median overall survival was 33.4 months for the tasquinimod group versus 30.4 months for the placebo group (p=0.49). [9] Using a multivariate analysis, treatment with tasquinimod was associated with an OS advantage with a HR of 0.64 (95% CI 0.42, 0.97, p=0.034). [9] It was hypothesized that the prolongation in PFS observed with tasquinimod treatment may lead to a survival advantage in men with metastatic CRPC. Also, a stronger trend for survival benefit was seen in patients with bone metastases; 34.2 for the tasquinimod group vs 27.1 months for the placebo group (HR 0.73, 95% CI 0.46, 1.17, p=0.19). [9]

Analysis of up to 3 years of safety data from phase II studies showed that treatment-related adverse events were mild to moderate, manageable and less frequent after 2 months of therapy. [7] Adverse events observed included gastrointestinal disorders, fatigue, musculoskeletal pain as well as elevations of some laboratory parameters. [7]

A phase III randomized controlled trial called 10TASQ10 [6] to confirm tasquinimod’s effect on disease progression is ongoing. More than 1,200 patients with asymptomatic to mildly symptomatic metastatic CRPC were successfully enrolled in the study, as planned in the clinical protocol. [7] The study is expected to complete in 2016. [6] Other indications are currently under investigation. [6] [19]

Related Research Articles

Nicholas J. Vogelzang was a medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN). He serves as Medical Director of the Research Executive Committee and Associate Chair of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research. His research interests include clinical trials for genitourinary malignancies and mesothelioma.

<span class="mw-page-title-main">Sunitinib</span> Cancer medication

Sunitinib, sold under the brand name Sutent, is a medication used to treat cancer. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.

<span class="mw-page-title-main">Ipilimumab</span> Pharmaceutical drug

Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.

<span class="mw-page-title-main">Satraplatin</span> Chemical compound

Satraplatin is a platinum-based antineoplastic agent that was under investigation as a treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U.S. Food and Drug Administration. First mentioned in the medical literature in 1993, satraplatin is the first orally active platinum-based chemotherapeutic drug; other available platinum analogues—cisplatin, carboplatin, and oxaliplatin—must be given intravenously.

<span class="mw-page-title-main">Abiraterone acetate</span> Chemical compound

Abiraterone acetate, sold under the brand name Zytiga among others, is a medication used to treat prostate cancer. Specifically it is used together with a corticosteroid for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC). It should either be used following removal of the testicles or along with a gonadotropin-releasing hormone (GnRH) analog. It is taken by mouth.

<span class="mw-page-title-main">Enzalutamide</span> Antiandrogen medication used in treatment of prostate cancer

Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), nonmetastatic castration-resistant prostate cancer, and metastatic castration-sensitive prostate cancer (mCSPC). It is taken by mouth.

Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types. By 2015 it had two US approvals for advanced cancers.

<span class="mw-page-title-main">Veliparib</span> Chemical compound

Veliparib (ABT-888) is a potential anti-cancer drug acting as a PARP inhibitor. It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments. Veliparib may make whole brain radiation treatment work more effectively against brain metastases from NSCLC. It has been shown to potentiate the effects of many chemotherapeutics, and as such has been part of many combination clinical trials.

<span class="mw-page-title-main">Cabazitaxel</span> Chemical compound

Cabazitaxel, sold under the brand name Jevtana, is a semi-synthetic derivative of a natural taxoid. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.

Sipuleucel-T, sold under the brand name Provenge, developed by Dendreon Pharmaceuticals, LLC, is a cell-based cancer immunotherapy for prostate cancer (CaP). It is an autologous cellular immunotherapy.

<span class="mw-page-title-main">Zibotentan</span> Chemical compound

Zibotentan is an experimental anti-cancer drug candidate in development by AstraZeneca. It is an endothelin receptor antagonist.

Carlumab is a discontinued human recombinant monoclonal antibody that targets human CC chemokine ligand 2 (CCL2)/monocyte chemoattractant protein (MCP1). Carlumab was under development for use in the treatment of oncology and immune indications and was studied for application in systemic sclerosis, atherosclerosis, diabetic nephropathy, liver fibrosis and type 2 diabetes.

EPI-001 is the first inhibitor of the androgen receptor amino-terminal domain. The single stereoisomer of EPI-001, EPI-002, is a first-in-class drug that the USAN council assigned a new stem class "-aniten" and the generic name "ralaniten". This distinguishes the anitens novel molecular mechanism from anti androgens that bind the C-terminus ligand-binding domain and have the stem class "lutamide". EPI-001 and its stereoisomers and analogues were discovered by Marianne Sadar and Raymond Andersen, who co-founded the pharmaceutical company ESSA Pharma Inc for the clinical development of anitens for the treatment of castration-resistant prostate cancer (CRPC).

PROSTVAC is a cancer immunotherapy candidate in clinical development by Bavarian Nordic for the treatment of all prostate cancer although clinical trials are focusing on more advanced cases of metastatic castration-resistant prostate cancer (mCRPC). PROSTVAC is a vaccine designed to enable the immune system to recognize and attack prostate cancer cells by triggering a specific and targeted T cell immune response to cancer cells that express the tumor-associated antigen prostate-specific antigen (PSA).

Darolutamide, sold under the brand name Nubeqa, is an antiandrogen medication which is used in the treatment of non-metastatic castration-resistant prostate cancer in men. It is specifically approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in conjunction with surgical or medical castration. The medication is taken by mouth twice per day with food.

<span class="mw-page-title-main">Apalutamide</span> Chemical compound

Apalutamide, sold under the brand name Erleada among others, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. It is specifically indicated for use in conjunction with castration in the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC). It is taken by mouth.

Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer.

<span class="mw-page-title-main">Ralaniten acetate</span> Chemical compound

Ralaniten acetate is a first-in-class antiandrogen that targets the N-terminal domain (NTD) of the androgen receptor (AR) developed by ESSA Pharmaceuticals and was under investigation for the treatment of prostate cancer. This mechanism of action is believed to allow the drug to block signaling from the AR and its splice variants. EPI-506 is a derivative of bisphenol A and a prodrug of ralaniten (EPI-002), one of the four stereoisomers of EPI-001, and was developed as a successor of EPI-001. The drug reached phase I/II prior to the discontinuation of its development. It showed signs of efficacy in the form of prostatic specific antigen (PSA) decreases (4–29%) predominantly at higher doses (≥1,280 mg) in some patients but also caused side effects and was discontinued by its developer in favor of next-generation AR NTD inhibitors with improved potency and tolerability.

Metronomic therapy is a new type of chemotherapy in which anti-cancer drugs are administered in a lower dose than the maximum tolerated dose repetitively over a long period to treat cancers with fewer side effects. Metronomic therapy is shown to affect both tumor microenvironment and tumor cells to achieve its therapeutic effects. Metronomic therapy is also cost-effective as a lower dose is used compared to conventional chemotherapy. The use of metronomic therapy has been extensively investigated and can be advantageous in selected group of patients. Yet, more clinical trials are necessary to generalize the method.

Lutetium (<sup>177</sup>Lu) vipivotide tetraxetan Radiopharmaceutical medication

Lutetium (177Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Lutetium (177Lu) vipivotide tetraxetan is a targeted radioligand therapy.

References

  1. ↑ Bratt O, Häggman M, Ahlgren G, Nordle O, Björk A, Damber JE (October 2009). "Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer". British Journal of Cancer. 101 (8): 1233–40. doi:10.1038/sj.bjc.6605322. PMC   2768463 . PMID   19755981.
  2. 1 2 3 4 5 Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N, et al. (December 2006). "Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer". The Prostate. 66 (16): 1768–78. doi:10.1002/pros.20509. PMID   16955399. S2CID   41648965.
  3. 1 2 Isaacs JT, Antony L, Dalrymple SL, Brennen WN, Gerber S, Hammers H, et al. (February 2013). "Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment". Cancer Research. 73 (4): 1386–99. doi:10.1158/0008-5472.CAN-12-2730. PMC   3578133 . PMID   23149916.
  4. 1 2 Källberg E, Vogl T, Liberg D, Olsson A, Björk P, Wikström P, et al. (2012). Lebedeva IV (ed.). "S100A9 interaction with TLR4 promotes tumor growth". PLOS ONE. 7 (3): e34207. Bibcode:2012PLoSO...734207K. doi: 10.1371/journal.pone.0034207 . PMC   3314596 . PMID   22470535.
  5. 1 2 Jennbacken K, Welén K, Olsson A, Axelsson B, Törngren M, Damber JE, Leanderson T (June 2012). "Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050)". The Prostate. 72 (8): 913–24. doi:10.1002/pros.21495. PMID   22287276. S2CID   40707516.
  6. 1 2 3 4 Clinical trial number NCT01234311 for "A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer" at ClinicalTrials.gov
  7. 1 2 3 4 5 "Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study in prostate cancer" (Press release). Active Biotech. 10 December 2012. Archived from the original on 4 January 2014. Retrieved 4 January 2014.
  8. 1 2 3 4 5 Pili R, Häggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, et al. (October 2011). "Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer". Journal of Clinical Oncology. 29 (30): 4022–8. doi:10.1200/JCO.2011.35.6295. PMID   21931019.
  9. 1 2 3 4 5 Armstrong AJ, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Polikoff J, et al. (June 2012). Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial (PDF). American Society of Clinical Oncology Annual Meeting. Chicago. Archived from the original (PDF) on 4 March 2016.
  10. ↑ Björk P, Björk A, Vogl T, Stenström M, Liberg D, Olsson A, et al. (April 2009). Akira S (ed.). "Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides". PLOS Biology. 7 (4): e97. doi:10.1371/journal.pbio.1000097. PMC   2671563 . PMID   19402754.
  11. 1 2 Isaacs JT (October 2010). "The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer". Expert Opinion on Investigational Drugs. 19 (10): 1235–43. doi:10.1517/13543784.2010.514262. PMC   4124623 . PMID   20836618.
  12. ↑ Dalrymple SL, Becker RE, Isaacs JT (May 2007). "The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts". The Prostate. 67 (7): 790–7. doi:10.1002/pros.20573. PMID   17373719. S2CID   41672865.
  13. 1 2 Olsson A, Björk A, Vallon-Christersson J, Isaacs JT, Leanderson T (May 2010). "Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors". Molecular Cancer. 9: 107. doi:10.1186/1476-4598-9-107. PMC   2885345 . PMID   20470445.
  14. ↑ "Active Biotech and Ipsen enter into a broad partnership for the co- development and commercialization of TASQ in" (Press release). Active Biotech. 18 April 2011. Archived from the original on 4 January 2014. Retrieved 4 January 2014.
  15. ↑ Murdoch C, Muthana M, Coffelt SB, Lewis CE (August 2008). "The role of myeloid cells in the promotion of tumour angiogenesis". Nature Reviews. Cancer. 8 (8): 618–31. doi:10.1038/nrc2444. PMID   18633355. S2CID   20327545.
  16. 1 2 Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, et al. (October 2008). "RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis". Carcinogenesis. 29 (10): 2035–43. doi:10.1093/carcin/bgn188. PMC   2556970 . PMID   18689872.
  17. 1 2 Rafii S, Lyden D (December 2006). "S100 chemokines mediate bookmarking of premetastatic niches". Nature Cell Biology. 8 (12): 1321–3. doi:10.1038/ncb1206-1321. PMC   2955889 . PMID   17139281.
  18. ↑ Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G (October 2008). "Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells". Journal of Immunology. 181 (7): 4666–75. doi:10.4049/jimmunol.181.7.4666. PMC   2810501 . PMID   18802069.
  19. ↑ Clinical trial number NCT01743469 for "A Study With Tasquinimod Treating Patients in Four Independent Cohorts of Hepatocellular, Ovarian, Renal Cell and Gastric Cancers" at ClinicalTrials.gov
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.